PEGylation of a Vesicular Stomatitis Virus G Pseudotyped Lentivirus Vector Prevents Inactivation in Serum

Journal of Virology

Volumn 78, Issue 2, 2004, Pages 912-921

  Croyle, Maria A ^a   Callahan, Shellie M ^a   Auricchio, Alberto ^b   Schumer, Gregg ^c   Linse, Klause D ^a   Wilson, James M ^c   Brunner, Lane J ^a   Kobinger, Gary P ^c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENT; ETHYLENE DERIVATIVE; GLYCOL; LENTIVIRUS VECTOR; MACROGOL; METHOXYPOLY(ETHYLENE)GLYCOL; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW; CONTROLLED STUDY; ESCHERICHIA COLI; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; SPLEEN; VESICULAR STOMATITIS VIRUS; VESICULAR STOMATITIS VIRUS G; VIRUS INACTIVATION; VIRUS PARTICLE; VIRUS TYPING;

ANIMALS; BONE MARROW; ELECTROPHORESIS, CAPILLARY; GENETIC VECTORS; HIV-1; HUMANS; IMMUNE SERA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; POLYETHYLENE GLYCOLS; SPLEEN; TRANSDUCTION, GENETIC; VESICULAR STOMATITIS-INDIANA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 0347949564     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.2.912-921.2004     Document Type: Article

References (53)

1. Adadevoh, K., M. Croyle, D. Malarme, E. Bonfils, and M. A. Bowe. 2002. A short-term field use and shipping stability study of a wild type Ad5 adenoviral reference material. Bioprocessing 1:62-69.
2. + cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 70:2581-2585.
3. Auricchio, A., G. Kobinger, V. Anand, M. Hildinger, E. O'Connor, A. Maguire, J. M. Wilson, and J. Bennett. 2001. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum. Mol. Genet. 10:3075-3081.
4. Bennett, J., D. Duan, J. F. Engelhardt, and A. M. Maguire. 1997. Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Investig. Ophthalmol. Vis. Sci. 38:2857-2863.
5. Beyer, W. R., M. Westphal, W. Ostertag, and D. van Laer. 2002. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis glycoprotein: generation, concentration, and broad host range. J. Virol. 76:1488-1495.
6. Bhadra, D., S. Bhadra, P. Jain, and N. K. Jain. 2002. PEGnology: a review of PEG-ylated systems. Pharmazie 57:5-29.
7. Burns, J. C., T. Friedmann, W. Driever, M. Burrascano, and J. K. Yee. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and non-mammalian cells. Proc. Natl. Acad. Sci. USA 90:8033-8037.
8. Cooper, N. R., F. C. Jensen, R. M. Welsh, Jr., and M. B. Oldstone. 1975. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J. Exp. Med. 144:970-984.
9. Croyle, M. A., N. Chirmule, Y. Zhang, and J. M. Wilson. 2002. PEGylation of first-generation recombinant adenoviruses achieves significant gene expression upon intravenous re-administration. Hum. Gene Ther. 13:1887-1900.
10. Croyle, M. A., N. Chirmule, Y. Zhang, and J. M. Wilson. 2001. "Stealth" adenoviruses blunt cell mediated and humoral immune responses against the vector and allow for significant gene expression upon re-administration in the lung. J. Virol. 75:4792-4801.
11. Croyle, M. A., B. J. Roessler, B. L. Davidson, J. M. Hilfinger, and G. L. Amidon. 1998. Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharm. Dev. Technol. 3:373-383.
12. Croyle, M. A., Q. C. Yu, and J. M. Wilson. 2000. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 11: 1721-1730.
13. DePolo, N. J., C. E. Harkleroad, M. Bodner, A. T. Watt, C. A. Anderson, J. S. Greengard, K. K. Murthy, T. W. Dubensky, and D. J. Jolly. 1999. The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J. Virol. 73:6708-6714.
14. DePolo, N. J., J. D. Reed, P. L. Sheridan, K. Townsend, S. L. Sauter, D. J. Jolly, and T. W. Dubensky. 2000. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol. Ther. 2:218-222.
15. Dull, T., R. Zufferey, M. Kelly, R. J. Mandel, M. Nguyen, D. Trono, and L. Naldini. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:8463-8471.
16. Gibaldi, M., and D. Perrier. 1982. Noncompartmental analysis based on statistical moment theory, p. 409-417. In Pharmacokinetics, nd ed., vol. 15. Marcel Dekker, New York, N.Y.
17. Gibaldi, M. and D. Perrier. 1982. Apparent volume of distribution, p. 199-219. In Pharmacokinetics, 2nd ed., vol. 15. Marcel Dekker, New York, N.Y.
18. Gusella, G. L., E. Fedorova, B. Hanss, D. Marras, M. E. Klotman, and P. E. Klotman. 2002. Lentiviral gene transduction of kidney. Hum. Gene Ther. 13:407-414.
19. Harris, J. M., N. E. Martin, and M. Modi. 2001. PEGylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40:539-551.
20. Higashikawa, F., and L.-J. Chang. 2001. Kinetic analyses of stability of simple and complex retroviral vectors. Virology 280:124-131.
21. Hoffman, L. M., A. M. Maguire, and J. Bennett. 1997. Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery. Investig. Ophthalmol. Vis. Sci. 38:2224-2233.
22. Igarashi, T., K. Miyake, K. Kato, A. Watanabe, M. Ishizaki, K. Ohara, and T. Shimada. 2003. Lentivirus mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther. 10:219-226.
23. Kafri, T. 2001. Lentivirus vectors: difficulties and hopes before clinical trials. Curr. Opin. Mol. Ther. 3:316-326.
24. Kafri, T., U. Blomer, D. A. Peterson, F. H. Gage, and I. M. Verma. 1997. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17:314-317.
25. Kang, Y., C. S. Stein, J. A. Heth, P. L. Sinn, A. K. Penisten, P. D. Staber, K. L. Ratliff, H. Shen, C. K. Barker, I. Martins, C. M. Sharkey, D. A. Sanders, P. B. McCray, Jr., and B. L. Davidson. 2002. In vivo gene transfer using a non-primate lentiviral vector pseudotyped with Ross River virus glycoproteins. J. Virol. 76:9378-9388.
26. Karali, T. T. 1995. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 16:351-380.
27. Kobinger, G. P., D. J. Weiner, Q. C. Yu, and J. M. Wilson. 2001. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 19:225-230.
28. Lotery, A. J., T. A. Derksen, S. R. Russel, R. F. Mullins, S. Sauter, L. M. Affatigato, E. M. Stone, and B. L. Davidson. 2002. Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors. Hum. Gene Ther. 13:689-696.
29. Mayo, K., D. Huseby, J. McDermott, B. Arvidson, L. Findlay, and E. Barklis. 2003. Retrovirus capsid protein assembly arrangements. J. Mol. Biol. 325: 225-237.
30. Miyoshi, H., M. Takahashi, F. H. Gage, and I. M. Verma. 1997. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. USA 94:10319-10323.
31. Naldini, L., U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
32. Ogris, M., S. Brunner, S. Schuller, R. Kircheis, and E. Wagner. 1999. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6:595-605.
33. Ohashi, K., F. Park, and M. A. Kay. 2002. Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction in vivo. Hum. Gene Ther. 13:653-663.
34. O'Riordan, C., A. Lachapelle, C. Delgado, V. Parkes, S. C. Wadsworth, A. E. Smith, and G. E. Francis. 1999. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10:1349-1358.
35. Page, K. A., N. R. Landau, and D. R. Littman. 1990. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J. Virol. 64:5270-5276.
36. Pan, D., R. Gunther, W. Duan, S. Wendell, W. Kaemmerer, T. Kafri, I. M. Verma, and C. B. Whitley. 2002. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol. Ther. 6:19-29.
37. Pepinsky, R. B., R. I. Shapiro, S. Wang, A. Chakraborty, A. Gill, D. J. Lepage, D. Wen, P. Rayhorn, G. S. Horan, F. R. Taylor, E. A. Garber, A. Galdes, and T. M. Engber. 2002. Long-acting forms of sonic hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model. J. Pharm. Sci. 91:371-387.
38. Poznansky, M., A. Lever, L. Bergeron, W. Haseltine, and J. Sodroski. 1991. Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector. J. Virol. 65:532-536.
39. Rigg, R. J., J. Chen, J. S. Dando, S. P. Forestell, I. Plavec, and E. Bohnlein. 1996. A novel human amphotropic packaging cell line: high titer, complement resistance and improved safety. Virology 218:290-295.
40. Rother, R. P., W. L. Fodor, J. P. Springhorn, C. W. Birks, E. Setter, M. S. Sandrin, S. P. Squinto, and S. A. Rollins. 1995. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J. Exp. Med. 182:1345-1355.
41. Rother, R. P., and S. P. Squinto. 1996. The alpha-galactosyl epitope: a sugar coating that makes viruses unpalatable. Cell 86:185-188.
42. Russell, D. W., M. S. Berger, and A. D. Miller. 1995. The effects of human serum and cerebral spinal fluid on retroviral vectors and packaging cell lines. Hum. Gene Ther. 6:635-641.
43. Stein, C. S., and B. L. Davidson. 2002. Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors. Methods Enzymol. 346: 433-454.
44. Streilein, J. W., S. Masli, M. Takeuchi, and T. Kezuka. 2002. The eye's view of antigen presentation. Hum. Immunol. 63:435-443.
45. Takahashi, M., H. Miyoshi, I. M. Verma, and F. H. Gage. 1999. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J. Virol. 73:7812-7816.
46. Taylor, A. W. 1999. Ocular immunosuppressive microenvironment., p. 72-89. In J. W. Streilein (ed.), Immune response and the eye, vol. 73. Karger, Basel, Switzerland.
47. VandenDriessche, T., L. Thorrez, L. Naldini, A. Follenzi, L. Moons, Z. Berneman, D. Collen, and M. K. L. Chuah. 2002. Lentiviral vectors containing the human immunodeficiency virus type-1 centro polypurine tract can efficiently transduce nondividing hepatocytes and antigen -presenting cells in vivo. Blood 100:813-822.
48. Verdier, F., and J. Descotes. 1999. Preclinical safety evaluation of human gene therapy products. Toxicol. Sci. 47:9-15.
49. Veronese, F. M. 2001. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22:405-417.
50. Wang, G., V. Slepushkin, J. Zabner, S. Keshavjee, J. C. Johnston, S. L. Sauter, D. J. Jolly, T. W. Dubensky, B. L. Davidson, and P. B. McCray. 1999. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct cystic fibrosis defect. J. Clin. Investig. 104:R55-R62.
51. Watson, D. J., G. P. Kobinger, M. A. Passini, J. M. Wilson, and J. H. Wolfe. 2002. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol. Ther. 5:528-537.
52. Woodle, M. C., C. M. Engbers, and S. Zalipsky. 1999. New amphipathic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug. Chem. 5:493-496.
53. Zhang, L., P. J. Dailey, A. Gettie, J. Blanchard, and D. D. Ho. 2002. The liver is a major organ for clearing simian immunodeficiency virus in rhesus monkeys. J. Virol. 76:5271-5273.